Efficacy versus safety: the dilemma of using novel platelet inhibitors for the treatment of patients with ischemic stroke and coronary artery disease.

Exploring potential anticoagulant drug formulations using thrombin generation test. Biochem Biophys Rep (2015) 0.75

Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation (2011) 31.98

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25

Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2009) 18.03

Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2007) 17.85

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet (1996) 16.32

Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2013) 14.49

An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med (1993) 11.11

Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke (2010) 10.66

Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet (2004) 9.41

The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet (1997) 9.34

Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med (2013) 8.76

Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med (2012) 4.49

Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med (2012) 4.10

Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet (2012) 4.02

Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol (2007) 3.72

Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med (2011) 3.20

Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation (2011) 3.16

Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. Circulation (2009) 2.93

Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost (2000) 2.45

The Secondary Prevention of Small Subcortical Strokes (SPS3) study. Int J Stroke (2011) 2.35

Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol (2008) 2.07

Antiplatelet use after intracerebral hemorrhage. Neurology (2006) 1.88

Efficacy and safety of vorapaxar in patients with prior ischemic stroke. Stroke (2013) 1.79

Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther (2009) 1.73

Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack. Circulation (2012) 1.66

What causes lacunar stroke? J Neurol Neurosurg Psychiatry (2005) 1.49

Platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trial: rationale and design. Int J Stroke (2013) 1.29

Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J (2006) 1.26

Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev (2007) 1.20

Incidence of stroke in Europe at the beginning of the 21st century. Stroke (2009) 1.19

Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects. Eur J Clin Pharmacol (2010) 1.13

A metaregression analysis of the dose-response effect of aspirin on stroke. Arch Intern Med (1999) 1.13

Platelet thrombin receptor antagonism and atherothrombosis. Eur Heart J (2009) 1.07

Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. Eur Heart J (2009) 1.04

Effect of clopidogrel plus ASA vs. ASA early after TIA and ischaemic stroke: a substudy of the CHARISMA trial. Int J Stroke (2011) 1.00

Association of ischemic stroke to coronary artery disease using computed tomography coronary angiography. Int J Cardiol (2011) 0.99

P2Y12, a new platelet ADP receptor, target of clopidogrel. Semin Vasc Med (2003) 0.98

Pharmacology of emerging novel platelet inhibitors. Am Heart J (2008) 0.96

Prescribing antiplatelet medicine and subsequent events after intracerebral hemorrhage. Stroke (2010) 0.94

Quality of care for acute coronary syndrome patients with known atherosclerotic disease: results from the Get With the Guidelines Program. Circulation (2009) 0.93

Impact of prior peripheral arterial disease and stroke on outcomes of acute coronary syndromes and effect of evidence-based therapies (from the Global Registry of Acute Coronary Events). Am J Cardiol (2007) 0.93

Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer? Circulation (2007) 0.87

A history of stroke/transient ischemic attack indicates high risks of cardiovascular event and hemorrhagic stroke in patients with coronary artery disease. Circulation (2012) 0.79

Stent thrombosis with drug-eluting stents: is the paradigm shifting? J Am Coll Cardiol (2013) 0.77

Treating patients with acute coronary syndromes with aggressive antiplatelet therapy (from the Global Registry of Acute Coronary Events). Am J Cardiol (2005) 0.76

Safety and efficacy of ezetimibe: A meta-analysis. Int J Cardiol (2015) 1.98

Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet (2013) 1.89

Spontaneous MI After Non-ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial. J Am Coll Cardiol (2016) 1.37

Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial). Am J Cardiol (2014) 0.80

Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial. Am Heart J (2016) 0.78

Bivalirudin or unfractionated heparin in patients with acute coronary syndromes managed invasively with and without ST elevation (MATRIX): randomised controlled trial. BMJ (2016) 0.78

Acute Kidney Injury After Radial or Femoral Access for Invasive Acute Coronary Syndrome Management: AKI-MATRIX. J Am Coll Cardiol (2017) 0.78